期刊文献+

瑞舒伐他汀对冠心病合并2型糖尿病患者血浆Omentin-1的影响 被引量:8

Effects of rosuvastatin on plasma omentin-1 levels in coronary heart disease patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的探讨冠心病(CHD)合并2型糖尿病(T2DM)患者血浆网膜素-1(Omentin-1)水平的变化及瑞舒伐他汀治疗对Omentin-1水平的影响。方法选择临床确诊的住院和门诊单纯T2DM患者42例和CHD合并T2DM患者47例。同期选择健康体检者37例作为正常对照组(NC组)。采用ELISA法测定所有研究对象及CHD合并T2DM组瑞舒伐他汀治疗后血浆Omentin-1水平,并分析血浆Omentin-1水平与白细胞介素6(IL-6)、空腹胰岛素(FINS)、体重指数(BMI)、内皮素(ET)、胰岛素抵抗指数(HOMA-IR)和一氧化氮(NO)等的关系。结果与NC组(24.79±6.18ng/ml)比较,CHD合并T2DM组治疗前(14.75±4.02 ng/ml)和单纯T2DM组(19.32±5.17 ng/ml)患者血浆Omentin-1水平均明显降低(P均<0.01),CHD合并T2DM组治疗前血浆Omentin-1水平显著低于单纯T2DM组(14.75±4.02vs.18.30±5.17 ng/ml,P<0.01)。CHD合并T2DM患者血浆Omentin-1水平与FINS、BMI、HOMA-IR、IL-6、ET呈明显负相关,与NO呈正相关(P<0.01或P<0.05)。HOMA-IR、IL-6和NO是影响CHD合并T2DM患者血浆Omentin-1水平的独立相关因素。CHD合并T2DM患者经瑞舒伐他汀治疗后TC、LDL-C、IL-6和ET均显著降低,而HDL-C和NO则显著增高(P<0.05),同时血浆Omentin-1水平也明显升高(18.35±3.97 vs.14.75±4.02 ng/ml,P<0.01)。结论瑞舒伐他汀在有效调节CHD合并T2DM患者脂代谢,减轻炎症反应,改善内皮功能的同时,升高血浆Omentin-1水平。 Objective To explore the effects of rosuvastatin on plasma omentin - 1 levels in coronary heart disease (CHD) patients with type 2 diabetes mellitus (T2DM). Methods Forty -two patients with uncomplicated T2DM, 47 CHD patients accompanied with T2DM and 37 subjects with normal control (NC) participated in this study. The relationship between plasma omentin - 1 levels and interleukin - 6 ( IL - 6 ), body mass index ( BMI), endothelin ( ET), HOMA - insulin resistance index ( HOMA - IR), nitric oxide (NO) was analyzed. After rosuvastatin treatment, plasma omentin - 1 levels were observed in CHD patients with T2DM. Results Patients with T2DM and CHD patients complicated by T2DM before the treatment had significantly lower plasma omentin - 1 levels than that of NC group ( 19.32 ± 5.17 vs. 24.79 ± 6.18 ng/ml and 14.75 ± 4.02 vs. 24.79 ± 6.18 ng/ml, respectively, all P 〈 0.01 ). CHD patients complicated by T2DM before the treatment had significantly lower plasma omentin - I levels than that of T2DM group ( 14.75 ± 4.02 vs. 18.30 ± 5.17 ng/ml, P 〈 0.01 ). Plasma omentin - 1 levels were negatively correlated with fasting insulin ( Fins), BM1, HOMA - IR, IL - 6 and ET and positively correlated with NO ( P 〈 0.01 or P 〈 0.05 ). HOMA - IR, IL - 6 and NO were the independent risk factors of plasma omentin - 1 in CHD patients complicated by T2DM. After rosuvastatin treatment, total cholesterol ( TC), low - density lipopretein cholesterol ( LDL - C), IL - 6 and ET were significantly decreased, and high - densi- ty lipoprotein cholesterol (HDL -C) and NO levels were significantly increased ( P 〈 0.05 ) in CHD patients complicated by T2DM. Moreover, plasma omentin - 1 levels were also significantly increased ( 18.35 ± 3.97 vs. 14.75 ± 4.02 ng/ml, P 〈 0.01 ). Conclusion Rosuvastatin can remarkably regulate lipid metabolism, reduce inflammatory reaction, improve endothelial function as well as elevate plasma omentin - 1 levels in CHD patients complicated by T2DM.
出处 《临床和实验医学杂志》 2014年第4期256-260,共5页 Journal of Clinical and Experimental Medicine
关键词 冠心病 2型糖尿病 网膜素-1 瑞舒伐他汀 内皮功能 Coronary heart disease Type 2 diabetes Omentin - 1 Rosuvastatin Endothelial function
  • 相关文献

参考文献7

二级参考文献104

  • 1Libby P. Inflammation in atherosclerosis[J].Nature ,2002 ;420:868.
  • 2Ridker PM, Rifai N, Stampfer M J, et al. Plama concentration of interleukin-6 and the risk of future myocardial infarction a,noiag apparently healthy men[J].Circulation ,2000 ; 101 : 1767-72.
  • 3Sipahi I,Tuzcu EM, Schoenhagen P, et al. Paradoxical increase in lumen size during progression of coronary atherosclerosis : observations from the REVER-SAL trial[J]. Atherosclerosis,2006 ; 189 ( 1 ) :229-35.
  • 4Hart SN, Leka LS, Lichtenstein AH, et al. Effect of hydrogenated and satu- rated, relative to polyunsaturated, tat on immune and intlammatory respon- ses of adults with moderate hypercholesterolemia[J].J Lipid Res,2002; 43:445-52.
  • 5LI jj, Fang CH. Atheroscleritis is a more rational term for the pathological entity currently known as atheroselerosis [J]. Med Hypotheses,2004 ;63: 100-2.
  • 6Takemoto M,Liao JK. Pleiotropic effects of 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors[J]. Arterioscler Thromb Vasc Biol ,,2001 ; 21 : 1712-9.
  • 7Musial J, Undas A, Gajewski P, et al. Antiinflammation effects of simvasatin in subjects with hypercholesterolemia[J].Int J Cardiol,2001 ;77:247- 53.
  • 8Ridker PM. Rosuvastatin in the primary prevention of cardiovascular dis- ease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein rationale and design of the JUPITER trial[J].Circulation ,2003 ; 108:2292-7.
  • 9Bonetti PO, Wilson SH, Rodriguez-Porcel M, et al. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experi- mental hypercholesterolemia independent of lipid lowering[ J]. J Am Coil Cardio1,2002 ;40:546-54.
  • 10Elisaf M. Effects of fibrates on serum metabolic parameters [J]. Curr Med Opin,2002 ; 18 (5) :269-76.

共引文献394

同被引文献74

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部